DK0773788T3 - Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner - Google Patents

Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner

Info

Publication number
DK0773788T3
DK0773788T3 DK96917968T DK96917968T DK0773788T3 DK 0773788 T3 DK0773788 T3 DK 0773788T3 DK 96917968 T DK96917968 T DK 96917968T DK 96917968 T DK96917968 T DK 96917968T DK 0773788 T3 DK0773788 T3 DK 0773788T3
Authority
DK
Denmark
Prior art keywords
neurotoxins
methods
admixtures
neurotoxin
compositions
Prior art date
Application number
DK96917968T
Other languages
English (en)
Inventor
L Bruce Pearce
Eric R First
Original Assignee
Allergan Inc
L Bruce Pearce
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Allergan Inc, L Bruce Pearce filed Critical Allergan Inc
Application granted granted Critical
Publication of DK0773788T3 publication Critical patent/DK0773788T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
    • A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
    • A61K38/4893—Botulinum neurotoxin (3.4.24.69)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Detergent Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
DK96917968T 1995-06-06 1996-06-04 Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner DK0773788T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46576795A 1995-06-06 1995-06-06
PCT/US1996/008534 WO1996039167A1 (en) 1995-06-06 1996-06-04 Improved compositions and methods for chemodenervation using neurotoxins

Publications (1)

Publication Number Publication Date
DK0773788T3 true DK0773788T3 (da) 2003-09-01

Family

ID=23849078

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96917968T DK0773788T3 (da) 1995-06-06 1996-06-04 Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner

Country Status (8)

Country Link
US (1) US6087327A (da)
EP (1) EP0773788B1 (da)
AT (1) ATE239491T1 (da)
AU (1) AU6034396A (da)
DE (1) DE69627963T2 (da)
DK (1) DK0773788T3 (da)
ES (1) ES2198484T3 (da)
WO (1) WO1996039167A1 (da)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW574036B (en) 1998-09-11 2004-02-01 Elan Pharm Inc Stable liquid compositions of botulinum toxin
US6545126B1 (en) * 1999-03-18 2003-04-08 Wisconsin Alumni Research Foundation Chimeric toxins
DE19925739A1 (de) * 1999-06-07 2000-12-21 Biotecon Ges Fuer Biotechnologische Entwicklung & Consulting Mbh Therapeutikum mit einem Botulinum-Neurotoxin
US6261572B1 (en) 2000-01-11 2001-07-17 Allergan Sales, Inc. Method for treating a pancreatic disorder with a neurotoxin
US6337075B1 (en) 2000-01-11 2002-01-08 Allergan Sales, Inc. Methods for treating diabetes
US6143306A (en) * 2000-01-11 2000-11-07 Allergan Sales, Inc. Methods for treating pancreatic disorders
US20060269575A1 (en) * 2000-02-08 2006-11-30 Allergan, Inc. Botulinum toxin pharmaceutical compositions formulated with recombinant albumin
US8632785B2 (en) * 2000-02-08 2014-01-21 Allergan, Inc. Clostridial toxin pharmaceutical composition containing a gelatin fragment
US20030118598A1 (en) * 2000-02-08 2003-06-26 Allergan, Inc. Clostridial toxin pharmaceutical compositions
EP1398038B2 (en) * 2000-02-08 2011-01-26 Allergan, Inc. Botulinum toxin pharmaceutical compositions
US20030138460A1 (en) * 2000-02-08 2003-07-24 Allergan, Inc Methods of treating animals with botulinum toxin pharmaceutical compositions
US7780967B2 (en) * 2000-02-08 2010-08-24 Allergan, Inc. Reduced toxicity Clostridial toxin pharmaceutical compositions
MXPA03000014A (es) * 2000-06-28 2004-09-13 Ira Sanders Metodos para utilizar con fines beneficiosos toxina tetanica en animales.
US7273722B2 (en) * 2000-11-29 2007-09-25 Allergan, Inc. Neurotoxins with enhanced target specificity
US7115399B2 (en) * 2001-07-31 2006-10-03 Allergan, Inc. Pinna reflex assay
US20030113349A1 (en) * 2001-12-18 2003-06-19 Coleman William P. Topically applied clostridium botulinum toxin compositions and treatment methods
US7022329B2 (en) * 2002-02-25 2006-04-04 Allergan, Inc. Method for treating neurogenic inflammation pain with botulinum toxin and substance P components
US7691394B2 (en) * 2002-05-28 2010-04-06 Botulinum Toxin Research Associates, Inc. High-potency botulinum toxin formulations
US20040009180A1 (en) * 2002-07-11 2004-01-15 Allergan, Inc. Transdermal botulinum toxin compositions
NZ540425A (en) * 2002-12-20 2009-03-31 Botulinum Toxin Res Ass Inc Pharmaceutical botulinum toxin compositions
US7276244B2 (en) * 2004-02-12 2007-10-02 Philip Radovic Methods of treating abnormalities of the first metatarsophalangeal joint of the foot
US20050220821A1 (en) * 2004-03-31 2005-10-06 Allergan, Inc. Pressure sore treatment
US8323666B2 (en) 2005-08-01 2012-12-04 Allergan, Inc. Botulinum toxin compositions
US8137677B2 (en) * 2005-10-06 2012-03-20 Allergan, Inc. Non-protein stabilized clostridial toxin pharmaceutical compositions
US8168206B1 (en) 2005-10-06 2012-05-01 Allergan, Inc. Animal protein-free pharmaceutical compositions
US9486408B2 (en) 2005-12-01 2016-11-08 University Of Massachusetts Lowell Botulinum nanoemulsions
US20070128226A1 (en) * 2005-12-01 2007-06-07 Philip Radovic Methods of treating pain associated with abnormalities of the first metatarsophalangeal joint of the foot
WO2009139739A1 (en) * 2006-02-14 2009-11-19 Government Of The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compositions comprising a combination of botulinum toxin a and botulinum toxin b for treating conditions characterized by unwanted or excessive presynaptic neuronal activity or secretion
US8658391B2 (en) 2006-04-27 2014-02-25 Anterios, Inc. Assessment of the effects of topical administration of chemodenervating pharmaceuticals
US20080113051A1 (en) * 2006-11-13 2008-05-15 Allergan, Inc. Methods for alleviating tattoo pain
CA2671447A1 (en) 2006-12-01 2008-06-12 Anterios, Inc. Amphiphilic entity nanoparticles
US9107815B2 (en) * 2008-02-22 2015-08-18 Allergan, Inc. Sustained release poloxamer containing pharmaceutical compositions
BRPI0914630A2 (pt) * 2008-06-26 2019-09-24 Anterios Inc liberação dérmica
EP2364168A1 (en) 2008-12-04 2011-09-14 Botulinum Toxin Research Associates, Inc. Extended length botulinum toxin formulation for human or mammalian use
US8129139B2 (en) 2009-07-13 2012-03-06 Allergan, Inc. Process for obtaining botulinum neurotoxin
KR20190014125A (ko) * 2011-01-24 2019-02-11 안테리오스, 인코퍼레이티드 나노입자 조성물, 이의 제형, 및 그의 용도
US9393291B2 (en) 2012-04-12 2016-07-19 Botulinum Toxin Research Associates, Inc. Use of botulinum toxin for the treatment of cerebrovascular disease, renovascular and retinovascular circulatory beds
US20140120077A1 (en) 2012-10-28 2014-05-01 Revance Therapeutics, Inc. Compositions and Methods for Safe Treatment of Rhinitis
US9901627B2 (en) 2014-07-18 2018-02-27 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
US11484580B2 (en) 2014-07-18 2022-11-01 Revance Therapeutics, Inc. Topical ocular preparation of botulinum toxin for use in ocular surface disease
MX2019002835A (es) 2016-09-13 2019-09-04 Allergan Inc Composiciones no proteínicas de toxina clostridial.
EP3541358A1 (en) 2016-11-21 2019-09-25 Eirion Therapeutics, Inc. Transdermal delivery of large agents

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5183462A (en) * 1990-08-21 1993-02-02 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
US5401243A (en) * 1990-08-21 1995-03-28 Associated Synapse Biologics Controlled administration of chemodenervating pharmaceuticals
WO1994000481A1 (en) * 1992-06-23 1994-01-06 Associated Synapse Biologics Pharmaceutical composition containing botulinum b complex
US5562907A (en) * 1993-05-14 1996-10-08 Arnon; Stephen S. Method to prevent side-effects and insensitivity to the therapeutic uses of toxins
ES2168302T3 (es) * 1993-06-10 2002-06-16 Allergan Inc Tratamiento de trastornos y estados neuromusculares con toxina botulinica de serotipo e.
CA2164626C (en) * 1993-06-10 2004-11-23 K. Roger Aoki Multiple botulinum toxins for treating neuromuscular disorders and conditions
US5512547A (en) * 1994-10-13 1996-04-30 Wisconsin Alumni Research Foundation Pharmaceutical composition of botulinum neurotoxin and method of preparation

Also Published As

Publication number Publication date
EP0773788B1 (en) 2003-05-07
US6087327A (en) 2000-07-11
ES2198484T3 (es) 2004-02-01
WO1996039167A1 (en) 1996-12-12
DE69627963T2 (de) 2004-03-04
DE69627963D1 (de) 2003-06-12
AU6034396A (en) 1996-12-24
EP0773788A1 (en) 1997-05-21
ATE239491T1 (de) 2003-05-15

Similar Documents

Publication Publication Date Title
DK0773788T3 (da) Forbedrede præparater og fremgangsmåder til kemodenervering under anvendelse af neurotoxiner
DE69940439D1 (de) Streptococcus pneumoniae proteine und immunogene fragmente für impstoffe
Ohishi Activation of botulinum C2 toxin by trypsin
ATE553118T1 (de) Modifiziertes clostridiumtoxin mit geänderter biologischer persistenz
Brown et al. Inhibition of protein synthesis by Shiga toxin: activation of the toxin and inhibition of peptide elongation
CA2296720A1 (en) Use of botulinum toxin in the preparation of a pharmaceutical composition for treating a prostate disorder in a mammal
ES2062812T3 (es) Composicion detergente enzimatica y metodo para estabilizar enzimas.
Assakura et al. Comparison of immunological, biochemical and biophysical properties of three hemorrhagic factors isolated from the venom of Bothrops jararaca (jararaca)
CA2406367A1 (en) Method for treating pain by peripheral administration of a neurotoxin
BG103977A (en) Low molecular rotamase enzymic activity inhibitors
WO2002008268A3 (en) Leucine-based motif and clostridial neurotoxins
PT966447E (pt) Moleculas pequenas uteis no tratamento de doencas inflamatorias
WO2001026736A3 (en) Intraspinal compositions containing botulinum toxin for treating pain
NO963508L (no) Urease-basert vaksine og behandling av Helicobacter-infeksjon
CA2424242A1 (en) Methods for treating muscle injuries
IS3824A (is) Protein með bundið polyethylen og aðferð til framleiðslu þess
ATE168273T1 (de) Verbesserte synthese von polymer-bioaktiven- konjugaten
DK0921785T3 (da) Kombination af syreproteaseenzymer og sure puffere og anvendelser deraf
DE60007001D1 (de) Neurotoxine zur behandlung von pankreatischen krankheiten
GEP20043200B (en) Therapeutic Agent Comprising a Botulinum Neurotoxin
AU4245097A (en) Multivalent vaccine for (clostridium botulinum) neurotoxin
BR9811099A (pt) Inibidores de urocinase
WO2001082961A3 (en) Methods for treating bone tumors
Worthington et al. Physical changes in the epsilon prototoxin molecule of Clostridium perfringens during enzymatic activation
FR2773478B1 (fr) Composition de teinture d'oxydation des fibres keratiniques et procede de teinture mettant en oeuvre cette composition